257 related articles for article (PubMed ID: 35242631)
1. High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare
Li Y; Duan P; Guan Y; Chen Q; Grenda A; Christopoulos P; Denis MG; Guo Q
Transl Lung Cancer Res; 2022 Jan; 11(1):100-110. PubMed ID: 35242631
[TBL] [Abstract][Full Text] [Related]
2. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
3. Case report: Two novel
Liao S; Sun H; Wu J; Lu H; Fang Y; Wang Y; Liao W
Front Oncol; 2022; 12():916315. PubMed ID: 35941871
[TBL] [Abstract][Full Text] [Related]
4.
Su C; Jiang Y; Jiang W; Wang H; Liu S; Shao Y; Zhao W; Ning R; Yu Q
Onco Targets Ther; 2020; 13():12515-12519. PubMed ID: 33311990
[TBL] [Abstract][Full Text] [Related]
5. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
Ning S; Shi C; Zhang H; Li J
Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
[TBL] [Abstract][Full Text] [Related]
6. Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report.
Gu X; Wang W; Wu W; Zhang Y; Shao L; Santarpia M; Christopoulos P; Myall NJ; Shi Z; Lou G
Transl Lung Cancer Res; 2022 May; 11(5):902-909. PubMed ID: 35693284
[TBL] [Abstract][Full Text] [Related]
7. Novel
Yan L; Zheng J; Pan Q; Liang Y; Yu P; Chen Q
Front Oncol; 2023; 13():1264820. PubMed ID: 37706178
[TBL] [Abstract][Full Text] [Related]
8. Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy.
Zhai X; Wu Q; Pu D; Yin L; Wang W; Zhu D; Xu F
Front Oncol; 2021; 11():782682. PubMed ID: 35070986
[TBL] [Abstract][Full Text] [Related]
9. Classical
Zhai X; Liu Y; Liang Z; Wang W; Qin T; Liu SV; Um SW; Luo F; Liu J
Ann Transl Med; 2022 Nov; 10(21):1180. PubMed ID: 36467355
[TBL] [Abstract][Full Text] [Related]
10. Case report: Novel
Xue F; Xu S; Jiang C; Kang M; Usman M; Zhu L
Front Oncol; 2022; 12():1019624. PubMed ID: 36267987
[TBL] [Abstract][Full Text] [Related]
11. Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report.
Zhou H; Xu B; Xu J; Zhu G; Guo Y
Front Oncol; 2021; 11():670907. PubMed ID: 34168990
[TBL] [Abstract][Full Text] [Related]
12. STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report.
Feng C; Zhou R; Liu F; Wang T; Liu S; Shao Y
Front Oncol; 2021; 11():700341. PubMed ID: 34490099
[TBL] [Abstract][Full Text] [Related]
13. Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel
Shen G; Du Y; Shen J; Zhang J; Xia X; Huang M; Shen W
Onco Targets Ther; 2021; 14():5471-5475. PubMed ID: 34992382
[TBL] [Abstract][Full Text] [Related]
14. Response of a Novel KANK1::ALK Fusion to Alectinib in an Advanced Lung Adenocarcinoma: A Case Report.
Tang Q; Li T; Ren F; Li X; Cao W; Yu H; Mao F; Cao C; Zu L; Xu S
J Natl Compr Canc Netw; 2024 Feb; 22(2):. PubMed ID: 38364363
[TBL] [Abstract][Full Text] [Related]
15. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
Liu Z; Wu Q; Li W; Li P; Huang L; Wang T; Zhou Q
Lung Cancer; 2023 Dec; 186():107386. PubMed ID: 37922771
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract][Full Text] [Related]
17. Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience.
Crvenkova S
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Sep; 41(2):29-36. PubMed ID: 33011694
[TBL] [Abstract][Full Text] [Related]
18. Concomitant double-fusion of PLEKHA7-ALK and INPP5D-ALK reveals favorable alectinib sensitivity in lung adenocarcinoma: a case report and literature review.
Li P; Ju X; Yang G
Discov Oncol; 2024 Feb; 15(1):43. PubMed ID: 38379102
[TBL] [Abstract][Full Text] [Related]
19. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
20. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
